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Summary 
 
Though the paradox between Human Rights and Intellectual Property Rights has 
been discussed, their relationship remains unclear. In this paper, to clarify the 
relationship between human rights and intellectual property rights in the process of 
globalization, I will examine the legislation and analyze the function of the legal 
regime we have today and present my arguments. 
The first Chapter is the introduction. I have set globalization as my background 
and discuss my topic in the limitation of economic changes brought by the process of 
globalization. On this ground, will give a milieu of global statute and society reality 
related to access to health in the globalization.  
The second chapter is the theories part, the essential theories and relevant terms 
have be cleared and recalled. I have give a comprehensive explain of the theories I 
will used in my topic, such as globalization, access to health, health democracy, 
equity and A2K movement. 
The third chapter is the normative part. I have examined the international human 
rights system and pointed out the relevant legal support for the equity access to health. 
These human rights like right to health and right to development should be treat as the 
fundamental rights for humans. It should be fulfilled universally. Besides, I have 
analyzed the intellectual property regime and figure out what we should revise under 
the direction of human rights. 
 Turn to chapter four, it is a function examination of all the theories and 
doctrines mentioned above. The interesting problems spurt from the unbalanced 
global economy statute will be discussed. To some extent, Global medicine gap 
caused by the price block should be seen as the bomb point for the unequal access to 
health. Although under the requirement of universal human rights, like health 
democracy, the intellectual property regime has raised so-called compulsory license to 
balance the global problem, there still leave a huge margin for us.  
Finally, in the fifth part, the subject about innovation and health democracy will 
be considered broadly related to both human rights law and intellectual property law.  
To conclude, the process of globalization raised the new problem for intellectual 
property and caused the inequity access to health worldwide. On the one hand, 
because the human rights standard regulated in the international law is universal and 
broadly, it supplied a mechanism for the international trade market to balance the 
terrible situation. On the other hand, the intellectual property regime should also take 
the human rights provision into account and to be changed to suit for the global 
society. 
 
Key Word:  Access to Health; Health Democracy; Human Rights; Intellectual 
Property; Globalization 
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Preface 
 
The exploration of the relationship between intellectual property and access to 
health has been steadily increasing in the related field as the process of globalization. 
Because access to health can be seen as the essential element of human rights, I hold 
the opinion that the human rights should be put in the center stage of this topic and we 
need new democracy named health democracy today. Only the intellectual property 
rights being contest within the human rights, can it be efficient and benefit for all in 
the global society.  
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1. Introduction  
 
How to connect Human Rights issues with Intellectual Property standpoint has 
sparked spirit debates in recent years. Though the paradox between Human Rights 
and Intellectual Property Rights has been discussed, their relationship remains unclear. 
These discussions have stirred up serious antagonism, above all developed and 
developing countries, and have been the cause of intensive debate in international 
conferences at international level. As health is a factor that is crucial to the survival 
and welfare of mankind in the globalization, so how to play its role as a promoter of 
development, how to treat Access to health in the Human Rights regime and how to 
balance the proportion of Access to health and Intellectual Property Rights among 
different economic unit has become an urgent problem.  
As a response to these topics, this paper therefore aims to take a broad look and 
give an analysis to both Human Rights regime and Intellectual Property Rights system 
with the subjects of the various balance issues. It will deal with the argument of the 
relationship of Access to health and Intellectual Property in the context of 
globalization. 
As far as I can see, currently, as the economic development and knowledge 
access movement, the world health situation is pessimistic and unbalance. Intellectual 
property seems to set a barriers for the all the access to health in some sense. And 
globalization enlarged this gap. On the other hand, access to health as the element of 
human rights should be fulfilled without any condition. Thus, it would be not hard to 
conclude that there should be a balance involvement between Access to health and 
Intellectual Property Rights in the era of globalization.  
 
1.1 Outline 
In the first two chapters I will give a milieu of global statute and society reality 
related to access to health in the globalization. The essential theories and relevant 
terms need to be cleared and recalled. Furthermore, in the third chapter, the provision 
of International Human Rights Law and Intellectual Property Law will be analyzed 
and explained. Turn to Chapter 4, the interesting problems spurt from the unbalance 
economy statute, such as global medicine gap and price related issues will be 
discussed. Finally, I will examine the relationship between accesses to health under 
the intellectual property law framework. The subject about innovation and health 
democracy will be considered in a broadened context of globalization. 
 
1.2 Background 
Before I go through the further discussion, I need to set a global background 
related to my analysis below, for example, the global health situation, intellectual 
property statue and the association of these concepts with development. When I 
discussed the issues exist in the globalization, I choose to narrow my topic on the 
economic perspective and used the international human rights and intellectual 
property as the supports for my arguments  
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1.2.1 Global health and intellectual property 
Nowadays, the global health crisis reflects widening inequalities within and 
beyond countries. The reason of increasing unequal access to health lies in the fact 
that the Intellectual Property Rights which are the protection of the private rights for 
the inventors or advance technology right holders in health care system has set the 
huge barrier for the poor to enjoy the benefit for free or in low price. In other word, 
the advantage science and technology can only secure a better health for a small 
fraction of the world’s upside population. Noticeably, the access to health is 
unbalanced and varying from country to country. 
According to the statistics given by WIPO 1, in 2011, USA, Germany and 
China 2occupied the first three places of the resident medicine patent application. 
Simultaneously, the health related situation update reflects that these countries indeed 
guarantee more comprehensive health access, such as health insurance (not the 
concern of this paper), comprehensive health instruction and access to advanced 
health resources like medicine and medical technology. That is to say, the intellectual 
property rights have a close relationship with access to health. The patent grants not 
only improve the innovation, but also provide an advanced health care. 
On the contrary, coincidently, the countries who own less medicine or health 
related patent maintains a seriously urgent health situation. Taking a glimpse of the 
global situation, approximately two billion people — one-third of the world’s 
population — have no access to the essential health they need nowadays because of 
the high price of the medicine and health care and patent protection of relevant 
technology. In some of the LDCs in Africa and Asia, it is even worse that the figure 
rises to more than half of the population. These statistics undeniably reveal the 
significant difficulty for the poor to access the technological advances created by 
humankind in the field of medical and health care. 
 On this ground, the intellectual property rightholder or advanced scientific 
technology definitely guarantees a higher protection and accessibility of health. Like 
the two sides of one coin, despite of the health guarantee and technology protection, 
the accessibility remains a major and priority challenge for the international 
community and intellectual property framework. 
1.2.2 Global society and access to health  
It is obviously that the paradox of intellectual property and access to health is 
raised through the process of globalization. In the other word, because we live in the 
global society, we need to balance the access to health and intellectual property rights 
under the direct of human rights principle.  
To illustrate, human beings have lived with a continual change since the 
migration of Homo erectus out of Africa a million years ago. And it is no doubt that, 
as the migration, we are already living in a global society now.3Thus, all the activities 
                                                             
1 WIPO. World Intellectual Property indicator. Geneva, 2011. 
2 Ibid. According to the data showed in the table of Contribution of field of technology to the change in volum of 
fillings (1995-2008), the pharmaceutical contribution of China, Germany, and United States occupied 6.5%, 6.3% 
and 8.8%, respectively. 
3 Kelley Lee. “Globalisation: what is it and how does it affect health?” The medical journal of Australia Med J Aust 
2004, 180 (4): 156-158. Available at: 
https://www.mja.com.au/journal/2004/180/4/globalisation-what-it-and-how-does-it-affect-health (access MAY 2012). 
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we have today will have an effect globally. This evolution of human societies is so 
called globalization. But the phrase, globalization of access to health, used in my 
paper is distinctive in its unprecedented intensity and extent of change. It focuses on 
the global influence raised by economic and knowledge movement.  
In addition, dramatic differences in the health and life chances of peoples around 
the world reflect imbalance in the power and prosperity of nations. And the 
individual’s health pertains not only to the individual, but also to the greater social 
organism. Hence, as the global changes, the undoubted social globalization initials 
profound unequal distributed of health related issues.  
Furthermore, in addition to globalization, access to health as an element of 
fundamental human rights also has the global characteristic, which guarantees the 
universal human dignity for all. The human rights require equity global accessibility 
without any excuse. Therefore, it formed the foundation for global health access in the 
globalization as well. 
So, it is no doubt that the access to health is not only an element of universal 
human rights, but also the requirement of global society. They are interacted.  
1.2.3 Health, economy and development 
Health has become not a condition of biology but one of social statues nowadays. 
It is important to the society development. 
 Health is not only an important indicator of the economic development of a 
society but also a determinant factor of the development: ‘more and more economic 
have come to recognize that the relationship between health and economic growth is 
not only demand driven, but that health itself is an important determinant if economic 
growth’.4 To be more specific, health related production is increasing characterized 
by the need to perform as an economic good5 with the scientific research tied to the 
market, both the development of the products and the decisions as to what products to 
investigate are influenced by profitability. The health demand will influence the 
research and innovation direction (discuss below). In recent days, as more and more 
attention has been put into health improvement according to the GDP growth, the 
economic value of the health products market has increased dramatically.  
Hence, health, economic and development has already formulated a triple-acting 
form with the globalization through the international trade market. this 
interrelationship between health and development is significant in the context of 
human rights, such as the right to development and right to food. These rights also 
incorporate health as an essential component, and ensure this relationship. 
 
1.3 Methodology 
In order to support my conduct the research, I have used following methods to 
get the information and database I need. 
                                                             
4 Zon, A. van, muysken, J.Health as a principle determinant of economic growth in Lopez-Casasnovas. 2005. G. et 
al. (ed). Health and economic growth: finding and policy implications. Cambridge MA: MIT Press, page 41. 
5 Lupton, D. Medicine as culture. 2003,2nd ed. London: SAGE, page 8-11. 
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(1) Information filter 
I should achieve as much as possible the current information. More specifically, 
literatures of fundamental theories, international instruments, reports and working 
papers, EU legislations and case law are mainly available from libraries and the 
internet. Chinese laws, policies, cases and industry reports are mostly within good 
reach in terms of the researcher’s Chinese background, although sometimes necessary 
translation work needs to be done. 
(2) Case study and legal interpretation 
I will give an examination of cases and legislations. It can be analyzed by means 
of conducting empirical research on current international and national resources 
concerning the subject.  
(3) Factual inquires  
The circumstances interviews and investigations will be taken for collection of 
advanced information and data. I will analyze these statistics and discuss the related 
issues with lead researchers from different fields. I try to make my research to be 
practical and efficient. 
(4) Comparative study  
I will compare different legal systems and interpret it in a practical way. I will 
attempt to consider the culture behind the law when I interpret the law and the case.  
(5) Synthesis and meta-analysis 
On the ground of the information I have got, I will give an analyze or a solution. 
 
 
Overall, as the society globalization, the health situation all over the world have 
appears new symbols and these society and economic changes have increased the 
unbalance of access to health under the protection of intellectual property. It turned to 
be an urgent task for the society to find an efficient international mechanism which 
can be universal and global accessed to relieve the pressure global situation. It cannot 
be denying that we can form an international intellectual property regime based on 
international human rights which is practical and useful in the globalization. 
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2. Theories  
 
There are many complicated theories is mixed up in the trend of globalization. 
And it is difficult to distinguish them separately. In this part I will clear several main 
stream concepts, like globalization, access to health, democracy, equity and A2K 
movement, and linked these expressions with international human rights law and 
intellectual law. These theories work to each other and have an inter-effect as well.  
 
 
2.1 Globalization 
2.1.1 Definition 
The term globalization usually is seen as a process driven by revolutions in 
communication and transportation.6The revolution makes it possible for people to 
move from here to there around the world, which will increase the economic and 
culture exchange.  
When discussing the globalization-health nexus, the term ‘globalization’ should 
be treated as a catch-all expression.7First, it is certain that the rise of multinational 
enterprises who want to take advantage of certain health production and distribution 
efficiencies is one of the key reasons for the health globalization. Besides, to the 
health issues associated to intellectual property market, globalization can be seen as a 
function of the simultaneous rise of significant amount of trade and investment. 
However, to focus on my topic, the globalization in my paper should been described 
as “a process of gradual integration within the world economy and culture through 
cross-border movements of goods, services and technology, which lead increasingly 
to economic decisions being influenced by global conditions.”8 The globalization 
through impacts on local cultures, attitudes, social behavior and contributes to the 
formation of global values, as well as to political participation, human rights 
fulfillment and the spread of democracy to get the world development integration.  
2.1.2 Effects of globalization 
The impact of globalization on access to health is mediated through different sets 
of factors.  
First, the policy and legislation of access to health has been changed with the 
globalization and occurred new symbols. To be specifically, the international and 
national policy factors which are consciously aimed at facilitating global economic 
integration are affecting health include the independent choices of economic agents in 
                                                             
6 Alejandro Portes. Globalization from Below: The Rise of Transnational Communities. WPTC-98-01. Princeton 
University, September 1997. 
7 Giovanni Andrea Cornia , Stefano Rosignoli , Luca Tiberti . Globalization Knowledge Network. Globalisation and 
Health: Pathways of Transmission and Evidence of Impact. WHO Commission on Social Determinants of Health. 
27 November 2006. 
8 Globalization Knowledge Network. Towards Health-Equitable Globalization: Rights, Regulation and 
Redistribution.2007. 
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the fields of consumption, health innovation, health and reproductive behavior, 
migration9, and so on. As the globalization, the policy and legislation should be set on 
the international level and the national legislation need to be amended by the way. 
 Second, because globalization affects how we perceive and experience physical 
or territorial space, which will increase the unbalance of achievement of health care 
due to the financial reasons and raise the pressure of local health resources 
consumption, so new legal regime for the market and re-balance lever should be built 
based on international human rights law.  
Third, globalization affects how we perceive and experience, which accelerate 
the information and knowledge achievement among the world. On the one hand, 
social interaction is speeding up through modern communication and transportation 
technologies. We need to share and open access our exclusive rights, such as some 
intellectual property rights. On the other hand, the globalization also offered a 
multinational payback for this open access.  
To conclude, as analyzed above, the globalization expressed in this paper is 
caused by the culture and economic change. It result many unbalanced distribution 
and unequal access. So the human rights doctrine should be taken into consideration 
without payback and laid the foundation of the legislation and policy needed in the 
globalization, because human right, particularly access to health, is the universal 
rights which can parallel10 with globalization.  
2.1.3 Globalization and access to health 
It would be inaccurate to describe globalization as either “good” or “bad” for 
health.  
For example, globalization affects the spread of disease. For high-income 
countries, the debate surrounding globalization and health tends to focus on the 
perceived threat from low- and middle-income countries, of acquiring certain acute 
and epidemic infections, such as HIV/AIDS, tuberculosis, plague and, more recently, 
severe acute respiratory syndrome (SARS). 11  Besides, the speed of modern 
transportation systems means that infections can potentially move around the world 
within a few hours (as illustrated by the SARS outbreak in 2002–03).12 However, the 
medical technical also spread with the occurring of the disease. And the modern 
technology potentially enables the health community to respond more quickly to such 
emergencies. For instance, an international network of institutions coordinated by the 
World Health Organization (WHO) via global telecommunications can readily detect 
                                                             
9  Giovanni Andrea Cornia , Stefano Rosignoli , Luca Tiberti . Globalization Knowledge Network. Globalisation 
and Health: Pathways of Transmission and Evidence of Impact. WHO Commission on Social Determinants of 
Health. 27 November 2006. 
10 The relationship among human rights, intellectual property and the trend and effect of globalization is 
cohesion and interaction, which can be seen as a parallel relationship. In other words, it is balanced. 
11 Institutes of Medicine. America’s vital interest in global health. Washington DC: National Academy Press, 
1997. 
12 Syed Q, Sopwith W, Regan M, Bellis MA. “Behind the mask: Journey through an epidemic: some observations 
of contrasting public health responses to SARS.” J Epidemiology Community Health ,57(2003): 855-856. 
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and rapidly respond to changes in the influenza virus.13 To response to these changes, 
it requires further international cooperation among countries and it need to create new 
or amend the current polity and legal system globally. We hope to build an efficient, 
equity and harmony regime under the human rights framework. 
Similarly, due to globalization, the migration appears throughout the world, 
which asked for equity access globally. Developed countries fear the potential 
financial burden of unhealthy populations migrating from the developing and least 
develop countries. There is also a tendency to overlook the benefits to high-income 
countries from population mobility — the migration of health professionals from 
poorer countries offers benefits to understaffed health systems in high-income 
countries (but at the expense of capacity in the developing world).14 In other words, 
the increased movement of people and other items creates a complex equation of 
pluses and minuses for each society. People all over the world need an equity access 
to health despite nationality, in-come and other personal condition. 
Finally, the cognition of health, ethic and human rights has been changed by 
globalization. The global advertising and marketing has result some new diseases, 
such as so-called “lifestyle” diseases, in certain populations within low- and 
middle-income countries. For illustrate, the shift in the tobacco pandemic to the 
developing world has been clearly driven by the tobacco industry.15 It is estimated 
that, by 2030, 70% of all tobacco-related deaths (7 million annually) will occur in 
developing countries.16 Nevertheless, global consciousness is also leading to the 
increased sharing of principles, legal values and standards that underpin decision 
making about health. In 1964, Helsinki declaration on ethical principles for medical 
research involving human subjects, the International code on the marketing of 
breast-milk substitutes adopted by the WHO and the United Nations Children’s Fund 
(UNICEF) in 1981, and the Framework convention on tobacco control adopted by the 
WHO in 2003. The concept of human rights has been spread with the health 
globalization. 
Therefore, as the international trade and economic harmony, we have to rethink 
the concept access to health in the context of globalization. This trend caused 
unbalanced access in the global range. We should value the ethic proportion in our 
activities related to health issues. And it is no doubt that the intellectual property law 
can play an essential role in this drift although some new changes need to be done 
complied with international human rights law. 
 
                                                             
13 WHO. WHO global influenza surveillance network. “Communicable Disease Surveillance and Response”. 
Geneva 2003. Available at: www.who.int/csr/disease/influenza/surveillance/en (accessed Jan 2012). 
14 Collin J, Lee K. Globalisation and transborder health risk in the UK: case studies in tobacco control and 
population mobility. London: The Nuffield Trust, 2003. 
15 Collin J. Think global, smoke local: transnational tobacco companies and cognitive globalization. In: Lee K, (ed). 
Health impacts of globalization: towards global governance. Palgrave Macmillan, 2002, page 61-85. 
16 WHO. “Confronting the epidemic: a global agenda for tobacco control research. Tobacco Free Initiative”. 
Geneva, 1999. Available at: whqlibdoc.who.int/hq/1999/WHO_NCD_TFI_99.12.pdf (accessed May 2012). 
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2.2 Access to health as the Element of Human Rights 
"Access to health", as a complex problem with many different aspects involved, 
cannot be reduced as a unilateral Intellectual Property Rights or Human Rights 
problem. This concept as a link of human rights and intellectual property should be 
seen as the most important element of the realization of some fundamental human 
rights.  
According to the General Comment 14, the right to health contains four elements. 
Obviously, the accessibility is the fundamental one there. Accessibility as the 
fundamental element has four overlapping dimensions: non-discrimination; physical 
accessibility; economical accessibility (affordability); information accessibility. It 
requests health facilities, goods and services accessible to everyone within the 
jurisdiction of the State party. 
Firstly, access to health does not mean the right to be healthy. Access to health 
means that governments must generate conditions under which everyone can be as 
healthy as possible. Such conditions range from ensuring availability of health 
services, healthy and safe working environments and adequate housing. Since health 
is a product of the combined action of a series of variables, some of them beyond 
human control, so access to health demands the right-holders to guarantee that the 
decision making have combined the situation, like good, medicine assistance, hygiene, 
health service and so on. According to General Comment 14, moreover, the access to 
health contains both freedoms and entitlements, which includes the right to be free 
from non-consensual medical treatment; the right to a system of health protection, the 
right to prevention, treatment and control of diseases; the right to healthy natural and 
workplace environments; and the right to health facilities, goods and services.  
Secondly, the expression of access means not only physical access but also active 
participation and manipulation. Participation in health-related decision-making at the 
national and international levels is another important entitlement. Equity of access 
should be measured in terms of the availability, utilization or outcomes of services. 
Both horizontal and vertical dimensions of equity need to be taken into consideration. 
In another word, not only what but also how to access should be considered by the 
actors. Non-discrimination and equality are critical components of the access to health. 
States have an obligation to prohibit discrimination and ensure equality to all in 
relation to access to health care and the underlying determinants of health. States must 
recognize and provide for the differences and specific needs of population groups, 
such as women, children, or persons with disabilities, which generally face particular 
health challenges, such as higher mortality rates or vulnerability to specific diseases. 
Overall, access to health has a "core content" referring to the minimum essential 
level of the human right. On this ground, we should turn the Intellectual Property into 
a supportive factor for the fulfilling of access. 
 
2.3 Democracy  
Democracy, like respect for human rights, is not an end in itself, but a means to 
individual and social development.17 Nowadays, the more people realize their right to 
                                                             
17 Dinah Shelton. “Symposium on the future of international human rights: challenges to the future of civil and 
political rights”. 55 Wash &Lee Law Review 669, 1998. 
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health, they ask for the more democracy of health through the court and government.  
The term “democratization”, according to O′Donnell and Schmitter, implies the 
application of the norms and procedures of citizenship to those institutions that have 
been governed by other principles, such as coercive control, social tradition, and 
judgment of specialists or bureaucratic processes. 18Democratization also implies 
applying these norms and procedures to individuals who did not always enjoy the 
benefits and duties of citizenship, such as women, young people and children, ethnic 
minorities or workers in the informal sector of the economy. Aristotle, in his work 
“Politics”, states that what defines a citizen is the possibility of holding office.19 In 
other sources, the term citizen is associated with a range of rights and duties, of a 
diverse nature, not only political, as defined within a constitution.20 In his “Class, 
Citizenship and Social Development”, Marshall recognizes three types of rights 
involved in the idea of citizenship: Civil, political, and social.21 Civil rights are those 
that define individual liberty: Freedom of thought and expression, the right to own 
property, and the right to an impartial trial. The institutions more directly related to 
civil rights are the courts. Political rights include the right to participate in the 
government of one’s own country. The procedures through which these rights are 
exercised include voting, free political competition, and access to public information. 
Finally, social rights include those rights that guarantee the participation in the social 
heritage, including the right to adequate housing, health, education, and culture. 
Marshall states that citizenship culminates with the implementation of social rights, 
which are delivered through institutions such as the educational and health systems.22 
So, just like the UNDP report has highlighted the efforts needed to incorporate 
these rights into legislation and ensure their implementation in ways which offer 
tangible benefits to all citizens.23It is no doubt that the reforms of extending the 
access to health to all the population have strengthened the procedures and institutions 
of democracy. Certainly, the democratization of health can contribute to the health of 
democracy.  
 
2.4 Balance and Equity 
It is certain that although Access to health and intellectual property seems to be 
contrary from certain perspective, we should build a human rights framework to make 
them balance and construct a win-win situation.  
This balance should be equity. To some extent, the balance does not necessarily 
mean equal distribution. For instance, when dealing with the same issue, such as 
                                                             
18 G. O’Donnell and P. Schmitter. ”Transiciones desde un gobierno autoritario”. Paidos, 1991, page 22–23. 
19 Aristotle. The politics. The University of Chicago Press, 1984, page 87.  
20 R. Scruton, A dictionary of political thought. London: Macmillan, 1996, page 71–72. 
21 T. H. Marshall. Class, citizenship and social development. Doubleday Anchor Books. 1965. 
22 Julio Frenk, Octavio Gómez-Dantés, Felicia Marie Knaulc. “The Democratization of Health in Mexico: Extending 
the Right to Health Care”. Swiss Human Rights Book. 25 May 2009. 
23 Julio Frenk and Octavio Gómez-Dantés. “The Democratization of Health in Mexico: Extending the Right to 
Health Care”. Swiss Human Rights Book. 25 May 2009. 
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Intellectual Property protection, in both developing country and developed country, 
different standards which accord to their local economy might be applied, owing to 
diverse problems stemmed from different economic and culture levels. Otherwise, 
equal application will only lead to inequality. 
So-called equity is frequently defined as an expression of social justice. It has to 
do fundamentally with a fair distribution of benefits from health and social 
development. It goes beyond equality of access to health care. It calls for responses 
that are in accord with the needs of the individual in relation to the needs for all.  
Furthermore, from the point of view of health, equity can be defined in various 
ways: a.) equal resources supply and expended for each individual; b.) equal resources 
expended for each case of a particular condition; c.) equal access to health services; d.) 
equal quality of health care; e.) equal status of health for all; f.) equal healthy life 
gained per dollar expended; g.) care according to needs and demand. Apparently, it 
involves both process and outcome. 24An operational approach would be to assess the 
impact of specific health decisions on equity and to ensure that decisions taken do 
enhance equity. Equity might not have a direct relation to aggregate health indicators.  
There are two perspectives on achieving equity. One is the "solidarity approach", 
which focuses on the society as a whole but may ignore or subjugate the needs of 
some members or groups. 25The opposite extreme to this approach is "the individual 
right approach" according to which each individual should have equal access to health 
care and equal outcome. It is obvious that this can only be achieved in a wealthy, 
politically stable community. Most third-world countries, which suffer the greatest 
burdens of disease, cannot fulfill these criteria. Sometimes the right of the individual 
to attain the highest state of health in a poor country would lead to inequities through 
exhausting the limited resources available for health in highly expensive health 
interventions. 26A balance has to be established where priority is given to support the 
basic health needs for the community. If the language of human rights were to be 
strictly adhered to in developing countries, it would set the good of the individual 
against the good of the whole community. The tension even exists in one of the richest 
countries, USA, where Lawrence Gostin notes that: "although public health 
authorities assuredly are empowered to constrain the freedoms and rights of 
individuals if necessary to achieve a collective good, they must do so consistent with 
constitutional constraints on government action. Achieving a just balance between the 
powers and duties of the state to defend and advance the public health and legally 
protected rights of human beings represents an enduring interest of those immersed in 
the discipline of public health law" 
As processes of globalization bring us closer together as peoples and nations, we 
begin to see the interdependence of our aspirations – aspirations for human security, 
including protection against poverty and exclusion, and aspirations for human 
freedom27, not just to grow and flourish as individuals but to grow and flourish 
together. So we recognize the value and necessity of collective action– nationally and 
                                                             
24 Mamdouh Gabr. “Health Ethics, equity and human dignity”. Available at : 
http://www.humiliationstudies.org/documents/GabrHealthEthics.pdf. (Accessed MAY 2012). 
25 Ibid. 
26 Ibid. 
27 Sen, 1999. See Carlos M. Correa. “Phamaceutical innovation, increamental, patenting and compulsory 
licensing”.  Availiable at : 
http://www.ungs.edu.ar/globelics/wp-content/uploads/2011/12/ID-246-Correa-Privatization-of-knowledge-Intell
ectual-Property-Right.pdf. (access MAY 2012). 
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globally – to correct the corrosive effects of inequality of life chances. This argument 
has been supported by the A2K movement as well. We need to share our knowledge 
product and use human rights spirits as a bridge for associating. It is not the 
requirement of the human dignity, but also the outcome of globalization. 
 
2.5 A2K: Health Is Knowledge 
Historically, knowledge is the essential element for all human activities and 
values, including freedom, economic, social and personal development. Knowledge 
goods, such as health related goods, are also fundamentally different from physical 
goods and services. For example, they are invisible but they can be copied. They 
should be shared and update daily. They are common and not scarce, everything is 
consisted by knowledge. All these characteristic lead to an equity access regardless 
the rich and the poor. 
Furthermore, when talking about knowledge in the legal system, intellectual 
property must be mentioned. Intellectual property as an organic system which is not 
only relevant to maximizing economic efficient but also resonates with immediate 
significance knowledge, which is the most useful legal tool made by the market 
associate with knowledge products. Access to these knowledge products, like 
medicines, as they are regulated through the intellectual property system raised 
numerous problems in the globalization. Therefore, the international organizations 
and other social organs launched the A2K movement to revise the relationship within 
the human rights framework. 
Admittedly, A2K is a coalition of civil society organizations, academics and 
other individuals that is concerned with facilitating access to knowledge as a 
fundamental principle of justice, freedom and economic development. In particular, 
A2K is especially addressing the relationship between private intellectual property 
rights and the possible obstacles to the rights to knowledge, education and public 
health. This has implications that knowledge being context of access to actual 
medicine product but also in term of access to scientific information, publications and 
medical research. While the A2K movement is concerned about fairness and access to 
knowledge, it also is supportive of creative and inventive communities. For example, 
the health related knowledge, like medicines, can be accessible through A2K and 
benefit the whole global society.  
But I have to point out that the “material interests” mentioned in A2K are not 
simply equivalent to current intellectual property provisions, not least because these 
rights are saleable and transferable, and therefore not “inalienable”. The right to 
access is ultimately the more important part of the right. Current levels of IP 
protection seem out of balance with Article 2728, according to A2K theorists: 
“... in a very real sense, rights delayed are rights denied. Had access to oral 
rehydration therapy and second-generation vaccine technologies been delayed for 
twenty years ... three million children would have died. Even for less life- and-death 
technologies, a twenty-year delay works an immense limitation on enjoyment of the 
right. For cultural works, the situation is even worse; protection lasts longer than a 
human lifetime.” 
                                                             
28Universal Declaration of Human Rights. Adopted and proclaimed by General Assembly 
Resolusion,G.Res.217A(III). 
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As to the question of access to health, the adoption of the Doha Declaration was 
another contributing step towards the emergence of a coordinated movement against 
the IP maximalist agenda of developed countries, as pushed by powerful IP exporting 
industries. It was also the beginning of a close link between the intellectual property 
and the access to health knowledge movement.   
 
 
Hence, as I claimed in this chapter, access to health as an essential element of 
human rights is a link between the global society, intellectual property rights and the 
human rights regime. In the process of globalization raised by migration and 
international economic movement, free and equitable to access the necessary health 
safeguard and enjoy the health democracy turned to a foundation of international 
cooperation on this point. But we still have a long way to go to balance this paradox 
between human rights and intellectual property rights. 
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3.  Legislation 
 
Historically, the debate on the relationship of Intellectual Property and Human 
Rights has laid distinctions between exclusive rights and universal rights. However, I 
argued that those discourses are balanced in the era of globalization. Access to health 
as an essential element of universal human right should not be violated by Intellectual 
Property. And the international legislation has given a clear answer to it. 
 
 
3.1 Intellectual Property Rights under the Human Rights Regime 
The term “access to health” is currently used in the context of Human Rights as 
an initial element, referring to different provisions stipulated in international treaties 
and fundamental Human Rights principles. “Access to health” as the realization of 
universal relative human rights, is supported by the International Human Rights Law I 
analyzed below. 
3.1.1 UDHR  
Health was identified as part of the inclusive right to an adequate standard of 
living in the Universal Declaration of Human Rights (UDHR).29 Obviously, as the 
global health economic movement, these definition of access to health and related 
human rights deviates from the conception of rights held in the18th and 19th centuries, 
which only restrained the state from actively denying citizens their basic civil and 
economic rights.30 
In article 25, it provides that everyone has “the right to a standard of living 
adequate for the health and well-being of himself and his family, including…medical 
care”.31  
At the same time, article 27 recognizes that “Everyone has the right to freely 
participate in the culture life of the community, to enjoy the arts and share in scientific 
advancement and its benefits.”32 
                                                             
29 Universal Declaration of Human Rights. Adopted and proclaimed by General Assembly 
Resolusion,G.Res.217A(III). 
30 Eide A, Alfredsson G, Melander, A, Rehof, LA, Rosas, A. (Ed). with collaboration of Swinehart, T. The Universal 
Declaration of Human Rights: A commentary. Scandinavian University Press , 1992, Page 385-404. 
31 Ibid. Universal Declaration of Human Rights .article 25(1) 
Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, 
including food, clothing, housing and medical care and necessary social services, and the right to security in the 
event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances 
beyond his control. 
32 Ibid. Universal Declaration of Human Rights .article 27 
 (1) Everyone has the right freely to participate in the cultural life of the community, to enjoy the arts and to 
share in scientific advancement and its benefits.  
(2) Everyone has the right to the protection of the moral and material interests resulting from any scientific, 
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UDHR contends that states must also take action to ensure that all citizens have 
the right to enjoy an adequate standard of living. It recognizes food, clothing, housing, 
health care and social services as essential components of a standard of living 
adequate for health and well-being as well. That is to say, the Access to health, 
recognized as an element of Human Right, provides not only a direct right to 
appropriate and timely health care, but also a right to access the underlying 
determinants of health, such as scientific benefits, care condition, and medicines. We 
shall to focus on the achievement of relevant scientific knowledge and how to raise 
the awareness of the approach for access to health. 
It is obvious that the access to adequate health operates directly or indirectly as a 
prerequisite to all other human rights recognized in treaties; to deny the access to 
health of someone can be seen as to deny or damage the other universal individual 
rights. Without health, individuals are denied their right to be contributing members of 
the community and to provide for their families. Individuals who lack adequate health 
care and have no health democracy guaranteed by ICCPR can thus lose some or all 
ability to exercise fully the civil, political, economic, social, and cultural rights they 
possess. 
3.1.2 ICESCR 
The International Covenant on Economic, Social and Cultural Rights (ICESCR), 
adopted 16 Dec 1966, established the right to public health as a fundamental Human 
Right. 
Regard to access to health, it contains a similar provision to UDHR, which states 
that the State parties should recognize the right of everyone to take part in culture life 
and to benefit from the protection of the moral and material interests resulting from 
any scientific production33.  
To be more specific, article 2(1)34 has pointed out the obligation of States, which 
includes the adoption of legislative measures where necessary to give the full 
realization of the rights recognized in the Covenant. It is worthy to say that although 
legislative measures are an important and necessary measure by which to guarantee 
the full effectiveness of the ICESCR, but other mechanisms also deserve to give a 
close attention. Significantly, the full realization of access to health should be 
                                                                                                                                                                              
literary or artistic production of which he is the author. 
33 International Covenant on Economic, Social and Culture Rights, article15(1) 
 The States Parties to the present Covenant recognize the right of everyone:  
(a) To take part in cultural life;  
(b) To enjoy the benefits of scientific progress and its applications;  
(c) To benefit from the protection of the moral and material interests resulting from any scientific, literary or 
artistic production of which he is the author. 
34 International Covenant on Economic, Social and Culture Rights, article 2 
1. Each State Party to the present Covenant undertakes to take steps, individually and through international 
assistance and co-operation, especially economic and technical, to the maximum of its available resources, with a 
view to achieving progressively the full realization of the rights recognized in the present Covenant by all 
appropriate means, including particularly the adoption of legislative measures. 
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undertaken “by all appropriate means”35 with the normative effect of the ICESCR 
together with the implementation of the provisions at the legislative level.36  
In particular, article 12(2)(c)37 refers to the entitlement to prevention, treatment 
and control of disease, and is defined as requiring the establishment of prevention and 
education program as well as a system of urgent medical care in the case of epidemics. 
Moreover, the right to health includes a right to facilities, goods and service, as 
provided article 12(2)(d)38. 
Besides, article 1539 ICESCR identifies a need to balance the protection of both 
public health and private interests and set forth that due the nature of access to health, 
it requires to be treated globally and universal. On one hand, article 15 recognizes the 
right of everyone to take part in culture life and to enjoy the benefits of scientific 
progress and its applications. On the other hand, it states the right of everyone to 
benefit from the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he or she is the author. Therefore, 
the ICESCR have struck a balance between promoting general public interest and 
private interest, which meet the paradox of human rights and intellectual property 
rights.  However, linked with the intellectual property regime, the international 
human rights law assurances the global and universal access which should be the 
standpoint of all the other legislation. The intellectual property provision should apply 
                                                             
35 CESCR, General Comment No 3,1990. 
36 Johanna Gilbson. Intellectual Property, Medicine and health. Ashgate public,2008, page 46. 
37 International Covenant on Economic, Social and Culture Rights,article 12(2) 
The steps to be taken by the States Parties to the present Covenant to achieve the full realization of this right shall 
include those necessary for:  
(a) The provision for the reduction of the stillbirth-rate and of infant mortality and for the healthy development of 
the child;  
(b) The improvement of all aspects of environmental and industrial hygiene;  
(c) The prevention, treatment and control of epidemic, endemic, occupational and other diseases;  
(d) The creation of conditions which would assure to all medical service and medical attention in the event of 
sickness.  
38 International Covenant on Economic, Social and Culture Rights. article 12. 
39 International Covenant on Economic, Social and Culture Rights. article 15  
1. The States Parties to the present Covenant recognize the right of everyone:  
(a) To take part in cultural life;  
(b) To enjoy the benefits of scientific progress and its applications;  
(c) To benefit from the protection of the moral and material interests resulting from any scientific, literary or 
artistic production of which he is the author.  
2. The steps to be taken by the States Parties to the present Covenant to achieve the full realization of this right 
shall include those necessary for the conservation, the development and the diffusion of science and culture.  
3. The States Parties to the present Covenant undertake to respect the freedom indispensable for scientific 
research and creative activity.  
4. The States Parties to the present Covenant recognize the benefits to be derived from the encouragement and 
development of international contacts and co-operation in the scientific and cultural fields. 
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an efficient way for all the people to enjoy the scientific benefit and access to equity 
health care, which should be treated as the universal and fundamental notification in 
that framework.  
But we cannot deny that the inequities still exist in our society. More than 30 
countries have not yet ratified the International Convention on Economic, Social and 
Cultural Rights and 60 countries do not recognize the access to health in their national 
constitution. 
3.1.3 General Comment No.14 
In 2000, the CESCR adopted General Comment No.14 on the implementation of 
ICESCR article 12, which sets that “Health is a fundamental Human Right 
indispensable for the exercise of other Human Rights. Every human being is entitled 
to the enjoyment of the highest attainable standard of health conductive to living a life 
in dignity”40. It defines the obligation of states so as to realize the universal human 
rights at the national level and the normative content named “the four essential 
elements”- availability, accessibility, acceptability and quality. It is the first time that 
the international authority has cleared and guaranteed accessibility as an essential 
element of all human rights, especially for health.  
Access to health which is the way for achieving opportunities and resources for 
health has been confirmed as an element of Human Right. According to the General 
Comment No.14, the right to health is not to be understood as a right to be healthy. 
The right to health contains both freedoms and entitlements.41 In this regard, General 
Comment No.14 has made special reference to the access to affordable health care, in 
particular essential drugs; HIV/AIDS; and national measures to promotion of the right 
to health. In the General Comment, it recalled international cooperation for finding 
the solution to solve the relevant health economic issues according to the international 
human rights law and cleared the relationship between international human rights law 
and intellectual property law, such as TRIPS. It also pointed out the human rights 
provision and standard as fundamental theories should be balanced and impressed in 
the intellectual property law and the global health economic market.  
Overall, as I pointed out above, because the human rights have a characteristic 
named universal access, so we should admitted that the international human rights law 
has already laid down a legislation foundation for the process of globalization. It turns 
to be the instruction of the global economic activities. We should give a universal 
respect to it.  
 
3.2 Human Rights in the Intellectual Property Rights Regime  
Turn to the intellectual property system, recently, because of the globalization 
has brought a lot of new problems into legal field, the legislator try to introduce the 
human rights law into the intellectual property regime. And the balanced relationship 
between Intellectual Property Rights and Human Rights has been indeed recognized 
by the international authority. Other than the solo performance of international and 
national patent law, an increasing number of treaties and international documents 
                                                             
40 CESCR, General Comment No 14,2000, Paragraph 8. 
41 Johanna Gilbson. Intellectual Property, Medicine and health. Ashgate public, 2008, page 50. 
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allow for space of “Access to health” and established many practical standards. 
3.2.1 TRIPS 
The WTO’s Agreement on Trade-Related Aspects on Intellectual Property Rights 
TRIPS established minimum standards of IP protection which all WTO Members 
have to comply with.  
TRIPS lays down standards for providing protection to patent holders, but these 
rights are not absolute. Although this agreement is not a particular intellectual 
property law related to access to health, it already draw the attention all over the 
world and provide many important and milestone solution to the fulfillment of 
universal human rights and balancing the unequal global intellectual property market. 
Moreover, like Dr. Gro Harlem Brundtland, director general of WHO, addressed:“The 
present regime of international trade agreements has been designed to strike a balance 
between the rights of patent holders and the rights of patients, and the TRIPS 
agreement contains important public health safeguards”.42  
TRIPS introduced numerous rules to ensure the people worldwide can access to 
the important patent in connection with health. 
Firstly, the term compulsory licensing actually used in the agreement is “other 
use without authorization of the right holder.” It allows governments to permit a 
person other than the patent holder to produce the product without the owner’s 
consent. If a compulsory license is issued, a market-rate fee must be paid to the patent 
holder, the license can be used only in the domestic market and must be rescinded 
once conditions change. Furthermore, in the event of a national emergency, a 
compulsory license can be issued without first trying to seek permission from the 
owner of the patent.43 
Secondly, governments can permit parallel importing, in which a product 
manufactured under a patent held in one country but sold at lower prices in another 
country can be imported from that second country without permission from the patent 
holder. TRIPS states that governments permitting parallel imports cannot be 
challenged under the WTO dispute settlement system, provided they do not 
discriminate on the grounds of the nationality of the patent holder.44 
Third, the “Bolar” provisions, namely permit on generic manufacturers to 
prepare production and regulatory procedures before patents expire so that products 
can be ready for sale as soon as the patent ends, rather than having to go through the 
lengthy preparatory process only after the patent period is over.45It is the essential 
way for the state to deal the emergency health crisis. And this provision has given a 
                                                             
42 Gumisai Mutume. Health and ‘Intellectual Property’ Poor nations and drug firms tussle over WTO patent 
provisions. Africa Recover, June 2001. See WIPO. FACT SHEET: TRIPS and pharmaceutical patents. Geneva, 
September 2006. 
43 Gumisai Mutume. Health and ‘intellectual property’ Poor nations and drug firms tussle over WTO patent 
provisions. Africa recovery, June 2001. See WIPO. FACT SHEET: TRIPS and pharmaceutical patents. Geneva, 
September 2006. 
44 Ibid. 
45 Ibid. 
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legal solution to the unbalanced global market.46  
Although some argue that the standards provide by TRIPS still create the barrier 
to access to health, for example, the flexibilities norms held that that members could 
implement at the national level, we have to say that the access crisis has existed since 
long before TRIPS came into force. Admittedly, TRIPS attempts to beat the unbalance 
between the long term social objective of providing incentives for the future 
inventions and creation and the short term objective of allowing people to use existing 
inventions and creations in the globalization. Obviously, it is almost successful. 
Access to health, on the perspective of globally, has already stroke the absolute 
control of the patent limitation and willing to build a balance platform due to TRIPS. 
The human rights have been put into consider and involved in the international 
decision-making. Conclusion can be made from the result of imply this agreement 
that the human rights theories indeed can adjust the intellectual property system and 
the global economic marketing. 
In spite of the entry into force of the TRIPS Agreement, the state of protection of 
pharmaceutical products is still not uniform throughout the world. Some countries had 
already amended their legislation, even before signing the Agreement. Some were 
compelled to do so by the risk of economic reprisals from their main trading partners, 
while still others acted in expectation of possible access to better and wider markets. 
The majority of the small, less developed countries, however, are making not 
amended their legislation.  
In the end, one important point should be mentioned as well is that some 
developed countries, especially the United States of America, insist that the provision 
of TRIPS still cannot provide sufficient protection for equity access to the global 
health market, so they advocated a bilateral arrangement that introduce a retroactive 
system where there has hitherto been no protection for pharmaceutical products and 
the law changes. And a period of grace is allowed during which it is possible to patent 
products that have already been patented in order countries, but have not yet been 
actually market in those countries. 47This system is known as the pipeline system, and 
has been introduced in the legislation of countries including Mexico and Brazil. 
3.2.2 The Declaration on the TRIPS Agreement and Public Health 
The Declaration on the TRIPS Agreement and Public Health (the Doha 
Declaration) adopted on 14 November 2001 during the WTO’s Doha Ministerial 
Conference attempted to give a political answer to the issue as to the relationship 
between IP and public health by recalling to members the existence of some so-called 
flexibilities that are contained in the TRIPS Agreement that members could 
implement at the national level. Furthermore, this Declaration clarified and interpreted 
some of the concepts provided under the TRIPS Agreement that were at the centre of 
disputes, such as, inter alia, compulsory license, situation of the national emergency, 
use of an exhaustion of rights regime.  
The Doha Declaration represents a major political victory for the developing 
                                                             
46 Ibid. 
47 Silvia Salazar. Intellectual property and right to health. 
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countries. Although it is only a political statement and does not modify the TRIPS 
Agreement in any way, it has important legal implications. It provides an 
understanding of the purpose of the TRIPS Agreement in relation to public-health 
issues that should guide any future rulings by WTO dispute-resolution panels dealing 
with such issues.48 The declaration gives developing-country governments a degree 
of security in adopting national-level measures necessary to meet public-health 
objectives, and several developing countries, such as Malaysia, Thailand, Indonesia, 
Brazil, Zimbabwe, and Ghana, have since taken advantage of compulsory licensing to 
gain access to affordable generic medicines.49 Many countries have also amended 
their laws to include the various TRIPS flexibilities. In other words, the Declaration 
acknowledged the importance of the public interests for Access to health by giving 
leeway to member countries to implement or interpret the TRIPS Agreement in a 
more flexible manner and they have the freedom to determine what a national 
emergency was. 
Today, the declaration has also become a common rallying platform for 
developing-country governments to take action to access affordable medicines and 
developed-country governments accountable for what they agreed to in Doha, 
particularly that “the TRIPS Agreement does not and should not prevent Members 
from taking measures to protect public health” and that “the Agreement can and 
should be interpreted to protect public health and in particular, to promote access to 
medicines for all.” 50 
According to the Doha Declaration, every state, no matter developing country or 
developed country, should keep an eye on balance the Access to health and 
Intellectual Property Rights, such as apply for the compulsory license regime. It 
addresses the restriction on the flexibility of the compulsory license in the context of 
Human Right to health51. 
Ellen’t Hoen has remarked that the Doha Declaration has had a galvanizing 
impact upon nation states:’ between 2001 and end 2007, 52 developing and LDCS 
have issued post-Doha compulsory licenses for production or import of generic 
versions of patented medicines, given effect to government use provisions, and/or 
implemented the non- enforcement of patents.’52 The Doha Declaration and the 
waiver have somewhat alleviated the deleterious impact of TRIPS on access to 
medicines. However, they have not completely solved the problem.53 For example, it 
is uncertain about the extent of the application of the Declaration and the waiver to 
                                                             
48 Correa, “Implications of the Doha Declaration on the TRIPS Agreement and Public Health.” 
49 Martin Khor, “Patents, Compulsory License and Access to Medicines: Some Recent Experiences”. February 2007. 
available at http://www.policyinnovations.org/ideas/policy_library/data/patents_compulsory_license (accessed 
March 2012). 
50 Doha Declaration on TRIPS and Public Health. Adopted on 14 November 2001, paragraph 6. 
51 Ibid, paragraph 4. 
52 Ellen’t Hoen, the global politics of pharmaceutical monopoly power: drug patents, access, innovation and the 
application of the WTO Doha Declaration on TRIPS and public health. 2009, xvi. 
53 See generally, Oxfam. “Patients versus Patents: Five years after the Doha Declaration.” Oxfam Briefing Paper 95 
(2006).  Available at  http://www. 
oxfam.org/en/policy/briefingpapers/bp95_patent_svspatients_061114.( Accessed April 2012). 
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health crises beyond epidemics; the TRIPS initiatives may do little to enhance access 
to drugs for sufferers of cancer or heart disease, or other lethal non-communicable 
diseases. 
The Doha Declaration was a political turning point in the way public health is 
governed globally, WTO Director-General Pascal Lamy said at the event’s outset, 
since the declaration’s adoption, the perception that intellectual property rights and 
public health has changed. 
The Doha Declaration and the waiver have somewhat alleviated the deleterious 
impact of TRIPS on access to medicines. However, they have not completely solved 
the problem.54 For example, it is uncertain about the extent of the application of the 
Declaration and the waiver to health crises beyond epidemics; the TRIPS initiatives 
may do little to enhance access to drugs for sufferers of cancer or heart disease, or 
other lethal non-communicable diseases. Indeed, the US threatened trade sanctions 
against Thailand in 2007 for its proposal to issue compulsory licenses with regard to 
medication for heart disease and cancer.55 Furthermore, by December 2008, only 
Rwanda had notified the WTO of an intention to make use of the waiver as an 
importing state.56 It may be that even generic drugs are too expensive for some states; 
that there is insufficient commercial incentive for generic manufacturers to produce 
drugs for such impoverished consumers; that pressure is being applied behind the 
scenes to discourage use of the scheme; or that there are delays in amending local 
legislation. Alternatively, the availability of the new scheme may be prompting 
pharmaceutical corporations, who feel threatened by compulsory licensing schemes, 
to make their products available to the least developed states on a cheaper, or even 
cost free, basis.57 Indeed, numerous corporations have adopted such a strategy.58 
First of all, The Doha Declaration has numerous advantages. 
The Doha Declaration addresses real and urgent problems faced by many 
developing countries in the area of public health. It is not intended to amend the 
TRIPS Agreement in any substantial manner. Rather, it aims to clarify the relationship 
between the TRIPS Agreement and Public Health policies of Member countries, and 
confirm the rights that Members have retained under the Agreement, particularly by 
defining the flexibility allowed in certain key areas. 
The Doha Declaration is a strong political statement that can make it easier for 
developing countries to adopt measures necessary to ensure access to health care 
without the fear of being dragged into a legal battle. The Declaration is also a 
Ministerial decision with legal effects on the Member States and on the WTO bodies. 
                                                             
54 See generally, Oxfam. “Patients versus Patents: Five years after the Doha Declaration.” Oxfam Briefing Paper 95 
(2006). Available at  http://www. oxfam.org/en/policy/briefingpapers/bp95_patent_svspatients_061114. 
(Accessed April 2012). 
55 Kevin Outterson. “Should access to medicines and TRIPS flexibilities be limited to specific diseases?” 34 
American Journal of Law and Medicine (2008): 279- 282. 
56 Canada notified the WTO that it would manufacture and export generic anti-HIV drugs to Rwanda. 
57 Adam McBeth. “When Nobody Comes to the Party: Why Have No States Used the WTO Scheme for 
Compulsory Licensing of Essential Medicines?”3 New Zealand Journal of International Law1 ( 2006): 23–30. 
58 See for example, http://www.diflucanpartnership.org/en/welcome/Default.aspx regarding Pfizer’s initiatives. 
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It states the purpose of the TRIPS Agreement in the area of public health, interprets 
the TRIPS Agreement with regard to some important aspects, instructs the Council for 
TRIPS to take action, and decides on the implementation of the transitional provisions 
for LDCs. 
Second, the problem existed in the Doha Declaration system. 
First one, the purpose of the Declaration has not been fulfilled. 
In the declaration, ministers stress that it is important to implement and interpret 
the TRIPS Agreement in a way that supports public health — by promoting both 
access to existing medicines and the creation of new medicines. But the Declaration 
itself does not make out the direct outline and resolve developing country concerns 
regarding access to medicines and TRIPS in practice. 
In addition, according to the third paragraph of the Declaration, which said “We 
recognize that intellectual property protection is important for the development of 
new medicines. We also recognize the concerns about its effects on prices”, it raised a 
controversial juxtaposition: patents are ‘important’, high prices raise ‘concerns’. 
Obviously, it is a relatively weak way of acknowledging that patents have negative 
consequences in the form of higher prices, thereby reducing access to medicines, 
particularly among the poor. Whether patent protection does indeed encourage 
research and development on drugs for diseases especially relevant to them has not 
been touched.  
Second one, the function of the Declaration, such as parallel importation, 
compulsory license, exhaustion and LDC. 
Since many patented products are sold at different prices in different markets, the 
rationale for parallel importation is to enable the import of lower priced patented 
products. Parallel importing can be an important tool enabling access to affordable 
medicines because there are substantial price differences between the same 
pharmaceutical products sold in different markets. The Doha Declaration has 
reaffirmed that Members do have this right, stating that each Member is free to 
establish its own regime for such exhaustion without challenge.  
This appears to leave each Member with the discretion to determine whether it 
will recognize compulsory-licensed marketing or sale of a product in a country of 
export as exhausting the patent holders’ rights in the country of import to consent to 
importation and resale. Although the Doha Declaration appears to resolve the issue of 
exhaustion based on marketing under compulsory license, it may be useful to consider 
the legal issues in more detail and give more limitation to it, such as give a limit on 
international exhaustion to marketing with the consent of the patent holder. However, 
since in adopting the Declaration, Members have exercised their exclusive 
competence to interpret a WTO agreement, and it would be extremely difficult to 
challenge the adopted interpretation. 
It should be stressed that the Doha Declaration is not self-executing and both 
developed and developing countries should adopt the legal amendments necessary to 
implement it. Developing countries, in particular, should ensure that they are using to 
the full extent possible the flexibilities allowed by the TRIPS Agreement to protect 
public health and facilitate access to health care by all. 
Then, turn to LDCs, the situation of LDCs received special attention at the Doha 
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Conference, but the paragraph 7 action item did not represent any significant 
improvement for the great majority of them. Hence, the problems faced by LDCs to 
gain access to needed pharmaceuticals are likely to require further consideration by 
the WTO Members, in order to accomplish the objectives sought by the Doha 
Declaration. 
Therefore, some arguments have been raised to propose to make the Declaration 
into a treaty. 
To be concluded, as explained above, although the Doha Declaration has 
connected intellectual property to Public Health and try to balance these two subjects, 
it still has a long way to go.  
3.2.3The Decision of 30 August 2003  
Art 31.f of TRIPS generally requires that a compulsory license must be limited to 
mainly supply the local market. This means that those countries do not have the 
capacity to manufacture pharmaceuticals products could not make use of the 
compulsory license flexibility. The TRIPS Council was therefore asked to find a 
solution to the problems faced by those countries with insufficient or no 
manufacturing capacities in the pharmaceutical sector that could face difficulties in 
making effective use of compulsory licensing under the TRIPS Agreement. On 30 
August 2003 the members of the WTO agreed unanimously on a solution to enable 
compulsory licensing of medicines for export. 
3.2.4 Amendment of the TRIPS Agreement 
The Amendment of the TRIPS Agreement59was agreed in December 2005. The 
agreement reached the agreement for a workable solution for compulsory licensing 
for export but maintains respect for Intellectual Property. It works out a balance in 
ensuring that the right holder can invest in Research & Development (R&D) for badly 
needed new vaccines and medicines for patients in the developing world, whilst 
allowing for compulsory licensing of patents where it is necessary for protect public 
health. 
According to the movement of revise, it reflects that “Access to health” under the 
structure of Intellectual Property regime plays a more and more important role in the 
global era. Duty holders are trying to find the more efficient and practical way to keep 
the balance and solve the flexible in both developed and developing country. The 
universal human rights theories can be find in all the intellectual property laws and 
still have a profound influence on them. It is not only the requirement of the global 
market which share the same nature with human rights, but also the need of the 
intellectual property. The fundamental human rights play an essential role in balance 
the economic proportion in the globalization and it is the bottom line of all kinds of 
social activities. 
Thus, we can conclude a trend from the revise timeline that the intellectual 
property rights have been discussed on the international level nowadays and more and 
more issues about success to health and implement of intellectual property limitation 
have been recognized. Consistent with the international human rights law I explained 
in 3.1, we find the cohesion of these two systems. And it has meet to the requirement 
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of globalization. 
 
 
To be conclude, because the trend of the globalization occurred in recent days, 
more and more policy and legislation should be enforced on the international level. 
Due to the universal and fundamental nature of human rights, the international human 
rights law should be treated as the basic standard of all other legal documents. And in 
contrast, the other international treaties or agreement must reflect and respect human 
rights principle. As we can see from these international legal documents I listed above, 
the provision given under the intellectual property have already taken the human 
rights such as access to health into account and intended to balance the unequal access 
among countries while we still need to amend them time after time. It is the demand 
of the globalization as well. 
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4. Problem Solving  
 
Nowadays, as the problems of balance access to health and intellectual property 
rights popped out spirit, it draws the attention from all social circles. Many strategies 
have been launched to reduce the downside influence bring by various economic 
situation and globalization, such as global drug strategy and implement of compulsory 
license. My analysis will use human rights, intellectual property and economy 
approach to explain how did the intellectual property and market trade affect the price 
of health related products and examine the function of the international law to explore 
the distinctive problem raised by the globalization. 
 
 
4.1 Global Access Requirement: Global Drug Gap  
4.1.1 Access to health and global drug gap 
The debate over access to health and lack of basic medicines takes place against 
the background of staggering health discrepancies: both between affluent and 
deprived countries and also, within the latter, between rich and poor.  
Among the world’s poor, some eighteen million die annually from a group of 
causes – communicable diseases, material and prenatal conditions and nutritional 
deficits which bring only minimal harm to the rich. Eighteen million is equivalent to 
just over 30 per cent of all human death. Life expectancy is 79.4 in the high- income 
countries and 49.2 in the Africa region.60 Similarly, dramatic health inequalities exist 
within the less developed countries. In Peru, under-five mortality is 11 per 1,000 
among the richest 20 per cent of the population versus 63 among the poorest 20 per 
cent, for example, and in Nigeria the corresponding figures are 79 versus 257.61 
The huge health discrepancies stem in part from the fact that poor people are at 
greater risk of diseases, due to lack of food, shelter, uncontaminated water, poor 
clothing and physical security. Another crucial factor is that the world’s poor have 
little access to health system and, in particular, to the medicines and health care that 
could help them cope with their debilitation and constant life-threatening conditions. 
To be explicit, this lack of access to essential medicines has three aspects. First, 
medicines for diseases aiming at the poor are neglected by pharmaceutical research. 
This phenomenon has come to known as the “10/90 gap”, alluding to the claim that 
‘only 10 per cent of global health research is devoted to conditions that account for 90 
per cent of the global disease burden’.62 In reality, most diseases and the need for 
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medicines necessity occurred in the poor countries. The second side of the access 
problem of the poor is that the existing medicines are, during their initial years on the 
market, typically priced vastly higher than their costs of production.63 Such high 
prices are partly due to patents, which grant the patentee the exclusive right to 
produce and distribute the medicine. Interestingly, this holds even within many poor 
countries, where the profit- maximizing price often excludes a majority of the national 
population.64 The third aspect of poor people’s lack of access to essential medicines 
is the dearth of basic minimally adequate local health infrastructure. In most LDCs, 
there is great scarcity of clinics and hospitals, of diagnostic equipments, as well as of 
doctors and nurses who are often actively recruited to move to more affluent countries. 
The effect of poor health infrastructure is that poor patients get no competent 
diagnosis and end up with no medicine at all, or with the wrong medicine, or with 
fake or diluted medicine, or without instructions about how to take the medicine to get 
optimal effect. 
Therefore, during the 1990s, to response to developing countries’ need to 
increase the availability and improve the use of medicines and fulfill “access to 
health”, WHO initiated a medicine policy called the “Revised Drug Strategy”. This 
Strategy was built mainly on the concept of “essential drugs”. The purpose of this 
strategy is to strengthen activities of the WHO in support of the action required to 
make drug use more reasonable throughout the world.65 The key elements that such a 
policy related to access to medicines should contain includes measures to improve the 
way medicines are regulated, measures to improve the way they move in international 
commerce, and measures to improve the way they are advertised and used. 66 
According to the WHO, essential drugs are "those that satisfy the primary health care 
needs of the population. They should be available at a price that the individual and the 
community can afford." 67 However, the meaning of “essential” and “afford” is 
difficult to interpret.  
Therefore, the WHO further recommends that "essential medicines are selected 
with due regard to disease prevalence, evidence on efficacy and safety, and 
comparative cost-effectiveness. Essential medicines are intended to be available 
within the context of functioning health systems at all times in adequate amounts, in 
the appropriate dosage forms, with assured quality, and at a price the individual and 
the community can afford." Inventions related to pharmaceutical products included in 
the WHO Model List of Essential Drugs—the Essential Medicines List—should not 
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be patentable.68 This measure was taken to prevent abusive pricing of essential 
medicines that could result from the new patent rules. 
The essential medicines concept can be applied in all countries and at various 
levels (national, provincial, district, hospital). It is especially valuable in 
poor-resource settings, as it allows one to get the best medicines for the resources 
available. The concentration on a few essential drugs has also lowered prices, due to 
economies of scale. 
To be more specified, about 95 % of the 300-odd medicines on the WHO’s list of 
essential medicines69are off-patent. Medicines on the list (divided into a core list and 
a complementary list) are “the most efficacious, safe and cost-effective medicines for 
priority conditions”. The list is supposed to be a practical tool for developing 
countries in deciding what medicines to procure. Thus, it does take the prices of 
medicines into account. However, some patented medicines may be excluded for this 
reason.70 
Obviously, “Access to essential medicines” is an indicator for the fulfillment of 
the access to health. In recent years two important mechanisms have been created to 
assess, as objectively as possible, the commitment and performance of governments 
towards the fulfillment of the right to health and both use access to essential 
medicines as an indicator. 71 Firstly, the UN High Commissioner for Human Rights 
has created sets of indicators for 12 aspects of human rights, including the right to 
housing and shelter, the right to education, the right to freedom of expression and the 
right to health 72 . Secondly, in 2008 The Lancet published a first independent 
assessment of the fulfillment of the right to health in all countries of the world73. Of 
72 indicators used, 8 measured access to essential medicines, largely taken from those 
used by WHO and by the UN High Commissioner for Human Rights. 
Apparently, the fundamental human rights constitutes important principles in our 
time and translate the values of equity, freedom, fairness, social justice and 
non-discrimination into practical entitlements for individuals, which increasingly 
guide public policies and national judicial systems. Human Right framework provides 
a different account of government duties on medicines that significantly re-prioritizes 
public needs for medicines. The provision of essential medicine is seen to place a core 
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duty on governments that cannot be traded with private property interests or domestic 
economic growth. The concept of essential medicines with its focus on equity, 
solidarity and social justice is already in line with the principles of human rights. Yet 
the daily practice of national essential medicine policies and programs can learn from 
the growing human rights movement and its emphasis on transparency, accountability 
and freedom from discrimination. But, the question who should pay for the invention 
and research is still a subject to debate. 
Indeed, the provisions of essential drugs under the WHO Action Program on 
Essential Drugs are identified as one of the core obligations to be met in order to give 
full realization to the access to health.74 However, access to health as recognized in 
the ICESCR is more than access to medicine. It also involves access to health care, 
access to food, access to health facilities and so on. For example, at least one third of 
the world’s population has no regular access to medicines. Inequity in access to 
essential medicines is only a part of the inequity in health care. Key evidence to 
document such inequities is rarely collected. More than 30 countries have not yet 
ratified the International Convention on Economic, Social and Cultural Rights and 60 
countries do not recognize the right to health in their national constitution. Therefore, 
beyond the promotion of strategy like “essential drug list” we should pay attention to 
improve other perspectives as well. 
At the same time, we can use the characteristic, like territory, limited scope, 
disclosure and exclusivity, of intellectual property to insure the other countries where 
the health products have not been grant the patent to get the use of the products. And 
of course, the LDCs need to increase the ability of innovation as well. They can use 
the open resources to improve their scientific technology according to the A2K 
movement I claimed in Chapter 2. 
4.1.2 Health democracy  
Health democracy can be seen as the enforceability of the right to access to 
health through the courts.75 The health democracy is the human rights basement for 
eliminate the global medicine gap. 
Most countries in the world have acceded to or ratified at least one global or 
regional covenant or treaty confirming the right to health. Ratifying such treaties 
creates binding State obligations and individual entitlements. However, what does this 
mean in practice? Can these individual entitlements be enforced through the courts? 
In 2006, the WHO presented the results of a systematic search to identify completed 
court cases in low- and middle-income countries in which individuals or groups had 
claimed access to essential medicines with reference to the right to health in general, 
or to specific human rights treaties ratified by their government.76 A total of 71 court 
cases from 12 countries were identified, mostly from Central and Latin America. In 
59 of these cases access to essential medicines as part of the fulfillment of the right to 
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health could indeed be enforced through the courts. The study concluded that the right 
to health cannot be restricted by limitations in social security coverage, that 
government policies have successfully been challenged in court, and that skillful 
litigation can help to promote that governments fulfill their constitutional and 
international treaty obligations, especially when governments are developing systems 
of social security. However, it should be noted that human rights accountability is 
more than the purely judicial accountability studied here. Sometimes referred to as 
“constructive accountability” this oversight may also include parliamentary 
committees, ombudsmen and national human rights institutions. 
4.1.3 Authority obligation 
Nowadays, inequity and discrimination in access to health remain the key public 
health challenge of our times. The national and international Authorities should fulfill 
their core human rights based responsibility through the law and policy. 77 
Specify the obligations of the authority and other stakeholders with regard to 
social welfare, the provision of health-care services and access to essential medicines. 
This will establish a further expression of authority commitment, and will also serve 
as a basis for planning, monitoring, transparency and accountability.78 
To illustrate, in my opinion, the government can collect and publish 
disaggregated statistics and targeted surveys to monitor access to essential medicines. 
Besides, they had better to create more necessary legal instruments for enforcement 
and redress to support different forms of accountability. 
Additionally, the UN, including the WHO, should also do some 
recommendations for countries on this issue. For instance, constant reporting on 
access to essential medicines in its annual reporting on progress in reaching 
Millennium Development Goal 8.2 which will continue to attract governments’ 
attention to essential medicines as part of the right to health and as part of achieving 
the Millennium Development Goals. What is more, prepare model texts for national 
constitutions on government commitment to the fulfillment of the right to health, 
including access to essential medicines. Political opportunities to update the 
constitution occur from time to time, presenting a chance to align national values and 
aspirations with international human rights standards. 
So, the national and international authorities need to work together in the trend of 
globalization and ensure the constitution and other legal provisions on the 
fundamental right to the enjoyment of the highest attainable standard of health, on the 
right to life and on the right to non-discrimination are in place, which will express and 
enshrine government values and commitments and will create a supportive 
environment for promoting and enforcing universal access. 79At the same time, the 
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authorities should enlarge the concept of democracy and involved the health 
democracy into context. This is the spirit of the ICESCR and ensured by the ICCPR. 
It will be the theories foundation of the global drug strategies and promote these 
activities. 
 
4.2 Global Access Obstacles: High Medicine Price and Related Issues  
Why do millions of people across the globe go without the treatments they need? 
The reasons are now becoming clear that the price and availability of medicines to 
those who need them are the crucial factors. Prices for poor people are simply too 
high and products are often not available. This may not be news to the sick and poor, 
but it has been news for those whose responsibility is to secure the health of 
citizens.80 
4.2.1 Market reality 
One third of the global population lacks reliable access to needed medicines81. 
The situation is even worse in the poorest countries of Africa and Asia, where as 
much as 50% of the population lacks such access. While some 10 million lives a year 
could be saved by improving access to essential medicines and vaccines – 4 million in 
Africa and South-East Asia alone82 – a major obstacle to achieving this goal is 
price.83 
Average per capita spending on pharmaceuticals in high-income countries is 100 
times higher than in low-income countries – about US$ 400 compared with US$ 4. 
The WHO estimates that 15% of the world’s population consumes over 90% of the 
global production of pharmaceuticals (by value)84.  
Not only are medicines unaffordable for large sectors of the global population, 
they are a major burden on government policy budgets. In developing countries today 
medicines account for 25–70% of overall healthcare expenditure, compared to less 
than 10% in most high-income countries85. Moreover, up to 90% of the population in 
low and middle-income countries must pay for medicines out of pocket due to lack of 
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social insurance and inadequate publicly subsidized services.86 Although medical 
policies are greatly needed to improve health infrastructure and financing as well as to 
ensure the rational use of medicines, high medicine prices are one of the biggest 
obstacles to access.87 
In many low- and middle-income countries, national medicine pricing policies 
have been shifting from price controls to deregulation under the influence of structural 
adjustment and reform programmed. Duties, taxes, mark-ups, distribution costs and 
dispensing fees are often high, regularly constituting between 30 to 45% of retail 
prices, but occasionally up to 80% or more of the total88. The higher the 
manufacturer’s contribution to the besides adding, the more these elements increase 
the market price.  
Additionally, prices of the same medicines frequently vary between countries89; 
some commonly used medicines have been found to be more expensive in developing 
countries than in industrialized ones90; and many studies have shown that 
affordability is unrelated to purchasing power. In other words, prices are influenced 
by factors such as whether the country observes patents and the level of flexibility 
allowed under international treaties. The monitoring of prices and cross-country 
comparisons are therefore important in the era of globalization. 
The difficulty in finding reliable information on medicine prices and availability 
– and therefore in analyzing their components – hinders governments in constructing 
sound medicine pricing policies or evaluating their impacts. It also makes it difficult 
for them to evaluate whether their expenditure on medicines is comparable to that of 
other countries at a similar stage of development.91 Moreover, those responsible for 
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purchasing medicines cannot negotiate cheaper deals because they have no sound 
basis from which to start their negotiation. Even in countries where consumers and 
patients have greater purchasing power, governments, insurance funds and hospitals 
often find it difficult to decide on the selection of medicines because they lack 
information, such as health knowledge, and health democracy. 92Therefore, I have to 
highlight that human rights theories can give a strong support in this problem. Access 
to health care which has been enshrined in international treaties and recognized by 
governments throughout the world is a fundamental human right. It recalled that all 
the people have the right to access to the health knowledge and related products. They 
also have the self-determination of it. 
4.2.2 The jurisprudential economic of price  
Pharmaceutical manufacturing is characterized by very high initial costs for 
research and development of new medicines and very low marginal costs for 
producing the medicines. The companies must recoup the initial costs by selling the 
units above marginal cost – at least in some markets. According to the “Ramsey 
pricing theory”, companies would however maximize sales in all types of markets if 
they adopted a differential pricing strategy. The initial costs would be mainly 
supported by the richer markets whereas markets with less capacity to pay would 
absorb marginal costs only. The poor markets would contribute to companies’ 
economies of scale, even if they cannot cover research costs.93 If Ramsey pricing was 
routinely practiced, as many as one out of three persons on Earth would probably not 
lack access to medicines. While most companies maintain differential pricing 
schemes, the effects are not systematic. Scherer and Watal found for example at best a 
very weak empirical relationship between medicine prices and country per capita 
income. In some developing countries, there were actually higher prices than in the 
US.94 The reason is that optimal pricing will only take place under the right 
conditions. Danzon and Towse argue that companies do not use Ramsey pricing 
because of the risk of parallel importation. Companies need to recoup costs in 
high-income markets, and this is not possible if low-priced products can be diverted 
from developing country recipients and “leak” back into high income markets. There 
is also the risk of “external reference pricing”, which occurs when high income 
countries use prices in developing countries as benchmarks for regulating their own 
domestic price levels. The rational response of the company when faced with the 
threats of parallel imports or external reference pricing is to set one international price 
that will apply to all markets. It will impede the possibility of selling to low income 
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markets, but guard the profit derived from the most important markets.95 The result is 
efficiency losses both for the company and consumers. Companies may view external 
reference pricing as an increasing threat due to developments in high income markets 
where aging populations and increased use of patented medicines are straining health 
budgets. There has been growing pressure for lower prices in the rich countries as 
well, for example in relation to disadvantaged people in the US.96 In many cases, it is 
also difficult to say what the Ramsey optimal price would be. Even in very poor 
countries, there may be a relatively large and growing middle class with higher 
purchasing power, which companies of course will want to exploit. The government 
response should be to separate the markets within the country, e.g. by letting only the 
poor access subsidized medicines through the national healthcare system. The 
problem in many developing countries is that the healthcare system is too weak to 
perform this role adequately, which again means that low-priced products may leak 
back to consumers that could pay more. 
4.2.3 Price and intellectual property 
Intellectual property rights reward monopoly rights to the creators of new 
products. Such regimes are said to encourage research, development and innovation, 
as they ensure that inventors can enjoy commercial benefits from their endeavors 
before being exposed to competition. 97  Intellectual property protection actually 
restricts competition, so intellectual property clauses are somewhat anomalous in 
trade agreements, which are normally designed to decrease trade barriers. Intellectual 
property rights nevertheless arguably facilitate trade. As traders are less concerned 
about pirating, global intellectual property rights promote foreign investment and 
technology transfer. However, as intellectual property laws confer monopoly rights, 
they generally inflate prices. This circumstance is problematic as goods that are 
essential for the enjoyment of human rights, such as new medicines, can be priced out 
of the reach of poor people. And it becomes more significant in the process of 
globalization.  
Thus, prices are likely to be artificially inflated for that 20 year period, as patent 
holders seek to maximize returns on their investment. For example, the costs of drugs 
which combat the HIV virus are enormous. A month’s worth of Atripla, a relatively 
new anti-HIV drug, costs USD 1300 a month.982 Such prices are only affordable in 
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industrialized countries due to government subsidies, which are not available in the 
developing world. Clearly, it is impossible for most people in the developing world, 
where most HIV cases arise, to pay such prices. The result is a health divide: HIV 
remains a death sentence for most sufferers in the developing world, whereas it can be 
managed for many years by sufferers in the developed world who have access to 
alleviating medication. 
Patent holder companies argue that the solution to high costs for the poor during 
a patent term is voluntary donations and differential prices, and these measures are a 
reason why the Decision has not so far been used. All the large pharmaceutical 
companies have programs for differential pricing and many donate large volumes of 
medicines to developing countries, in particular the LDCs. However, for a disease that 
persists it is not sustainable, and if the disease is widespread (such as AIDS), the 
donations can never fully meet the demand.99 The companies can only donate a 
certain amount before it starts affecting their overall ability to make a profit and 
continue in the market.  
In addition, there is currently an international system of price discrimination 
even if it does not generally result in systematic links between price levels and a 
country’s level of development. Sometimes there are large price differentials between 
equally poor countries as well, depending on geographic location. This price 
discrimination takes place even though there is a risk of high income markets prices 
being influenced. Incentives to lower prices may not be strong enough in the current 
situation where markets are not perfectly separate unless these threats are credible.100 
Thus, while donations and differential pricing are extremely important for improving 
access they cannot be the full or only solution for each and every poor country, or for 
every product. 
Hence, in my opinion, the voluntary system used today cannot result systematic 
adjustment of price in different market and make it as a unit international market due 
to globalization and universal human rights requirement. We do need apply a global 
and universal legislation mechanism and revise the international intellectual property 
system to balance the price. 
 
4.3 Global Access Guarantee: Compulsory License 
As discussed above, the different and vary of accessibility price has set a block 
on the way of fulfill access to health and other fundamental human rights globally. To 
some extent, one person out of three on Earth has no access to essential medicines. 
And the basic reason is of course poverty – many developing country consumers do 
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not have enough purchasing power. 101 Despite of the market, we also lack of 
international problem solving mechanism. The national policy and private interest 
intellectual property rules vary from country to country, which is not compatible to 
the economic globalization today. However, attributable to the human rights 
framework, all human beings should have the right to ensure their human dignity, and 
in this case, had the right to access to health, nevertheless they have the purchasing 
power. So, the intellectual property system raised a concept of compulsory license, to 
change to be a promotion mechanism for this trend but not block it. 
4.3.1 Background 
In respect to intellectual property law, a patent is an exclusive right to an 
invention with the purpose of stimulating research and development of new products. 
For illustrate, medicines are expensive to develop but relatively cheap to produce. The 
owners are therefore dependent on patent protection, a legal monopoly which the 
patent holder can exploit, to best advantage to be able to set prices that can recoup the 
investment made in research and development. 102The research-based industry can to 
some extent control prices and availability worldwide because more and more 
countries have introduced patent protection for medicines in the last decade. It makes 
sense economically for companies to adjust prices to different markets depending on 
their purchasing power: higher prices in high income countries and lower prices in 
developing countries. Such price differentiation allows production of larger volumes 
which leads to economies of scale. It benefits the companies at the same time as it 
provides better access to the product for consumers.103 
However, the theoretical model does not always work in real life. There are 
sometimes large price differentials between equally poor countries and occasionally 
prices are even higher than in high income countries. The explanation for this paradox 
is that the ability of companies to adjust prices according to purchasing power is 
circumscribed for two reasons. Firstly, because there is a risk that medicines sold at 
lower prices in developing countries are re-exported to high income markets. 
Secondly, there may be an indirect influence. Many high income countries, including 
Sweden, regulate medicine prices on a national level. There is a risk that these 
countries use prices in developing countries as benchmarks (external reference 
pricing). In both cases, prices are undermined in the most important markets which 
make it more difficult for companies to use prices in high income countries to cover 
research costs for new medicines.104 
To solve this unbalance and give an initiative to involve human rights standard in 
to intellectual property, in 2003, the WTO approved a set of new rules intended to 
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improve access to medicines in developing countries. One of them, so- called 
“compulsory license” is mentioned in the TRIPS.( in Chapter 3) It was a response to 
criticism that the WTO rules were part of the obstacles to increased access to essential 
medicines.  
One general restriction in TRIPS on compulsory licenses is that the license 
should be issued “predominantly for the supply of the domestic market.” This 
provision was problematic, as numerous developing states have no capacity to 
manufacture generic pharmaceutical products. Such states could not import 
compulsorily licensed products because other states were prohibited from producing 
such goods primarily for export.105 Furthermore, the WTO waived the territorial 
restriction on compulsory licenses for pharmaceutical products in certain 
circumstances. Under the waiver, the territorial restrictions on compulsory licenses 
may only be lifted to facilitate the export of generic drugs to the least developed 
countries in respect of pharmaceuticals to combat epidemics. Safeguards must be in 
place to ensure that the relevant pharmaceuticals are not diverted to another market.106 
Patent holders may allow others to exploit their inventions by granting voluntary 
licenses. Thus, the purpose of the compulsory license is to provide a safeguard against 
lack of use of a patent or misuse of the patent holder’s monopoly rights. 
Moreover, Article 31 in the TRIPS agreement allows the granting of compulsory 
licenses, as long as certain procedures are followed and certain terms fulfilled. So the 
compulsory license shall be considered on its individual merits and be possible to 
appeal. It may constitutes a strategic tool for improving the negotiating position of the 
general public towards the patent holder in order to improve access to a particular 
invention. There is, however, a risk that compulsory licenses reduce innovation and 
investment by diminishing the value of a patent.107(Analyze in the next Chapter) 
4.3.2 Effect 
The pharmaceutical industry has become highly concentrated through mergers 
and acquisitions in the last decades. Companies have sought to insure themselves 
from high costs and risks by growing. Coupled with the full implementation of TRIPS, 
which has extended patent protection to almost all countries, it is now possible for the 
big companies to exercise a high degree of control over prices and availability 
worldwide.108 So, how could compulsory licensing affect the access to health on the 
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economic perspective in the globalization? 
In what way could a compulsory license improve access to medicines? There are 
two potential scenarios where a compulsory license may result in lower prices. 
In the first scenario, compulsory licenses would result in lower prices due to 
lower development costs for the new producer. Unlike the patent holder, the new 
producer has no research costs to cover, only costs for starting a production. The new 
producer only has a license to sell the product in the market where the compulsory 
license is granted, and thus does not need to be concerned about any influence on 
prices in high income markets. In the second scenario, the compulsory license is not 
actually put into use. Its mere existence improves the negotiating position of the 
importer towards the patent holder, enabling the latter to reduce its own prices.109 
4.3.3 Lessons learned 
It is no doubt that although the compulsory licenses as a intellectual property 
tools did result in certain downward pressure on prices, it not always in a significant 
way. The compulsory licensing is only effective if the market is credible and 
important to the patent holder. To instance, the research on the general use of 
compulsory licenses in Canada, the US, Thailand, Malaysia, Zimbabwe and Brazil 
shows that while systematic use of compulsory licenses might harm innovation and 
investments, sporadic use showed no such effects.110 So despite the legal regulation 
like compulsory license, to balance the access problem and the intellectual property 
protection, another important factor should be considered collectively is how 
important the market in question is for investment decisions, which are the 
requirement of universal human rights and the production of globalization. The 
compulsory license cannot guarantee lower prices, if we apart the patent situation and 
costs of production from the unequal global market. 
Finally, I have to highlight that the rule must be implemented in national 
legislation before they can be utilized. Implementation is furthermore fully voluntary. 
On the exporter side, only Canada, Norway, India and the EU have implemented the 
rules so far. China have also made changes, but not formally notified their new laws 
to the WTO. There is little information on the legal situation in most potential 
importing countries. Many of them can probably use the new rules on the basis of 
existing laws and regulations on compulsory licenses. No attempt to import under the 
new rules has been completed in the four years that have passed since they were 
adopted. The organization Médecins Sans Frontières/Doctors without borders applied 
for a compulsory license in Canada for export of an AIDS medicine on behalf of an 
unnamed developing country. The organization abandoned the attempt when two 
Indian companies began marketing copies of the same medicine at a certified quality. 
These companies did not need to apply for a compulsory license since the medicine 
                                                             
109 The WTO Decision on Compulsory Licensing: Does it enable import of medicines for developing countries with 
grave public health problems?. Kommerskollegium,2008:2. 
110 Ibid. 
44 
 
was not patented in India. All in all, there appears to be a general lack of interest in 
using the new rules, even though the negotiations appeared to be so important to 
many parties. It is possible that the rules have had indirect effects even though they 
have not been used. The new possibility for compulsory licenses can improve 
importers’ negotiating positions, and the mere adoption of the new rules could 
therefore result in lower prices.111 However, it is not easy to discover such systematic 
price effects during the short period that has elapsed. So, because the market and 
global trade situation is changing from time to time and different countries have 
different national legislations, we need to improve this intellectual property system 
with the change of the globalization and under the direction of universal human rights. 
We should propose a international to national mechanism to ensure the use of this 
tools. 
The conclusion is that the compulsory license is a useful tool in nowadays. It can 
be an efficient formulation of the people to access to fundamental health resources 
and indeed balance the intellectual property rights with public health situation. It 
decreases the gap between the rich and the poor and reduces the certain price of the 
health related products. What’s more, due to the globalization, we also need to 
associate it with international trade risks and global limitations.  
 
 
So far, more and more activities and legal mechanism has been raised by 
different social organs, such as the WHO, the WIPO and the WTO. The globalization 
also accelerates the speed of international cooperation. Obviously, there still has 
margin left for the intellectual property law to revise on the perspective of balance 
access to health. And human rights principle should be the direction and aim for their 
promotion.  
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5. Discussion 
 
After the examination of the legal system and social strategies, I need to reveal 
the new and existing obstruct for access to health and intellectual property. Set on the 
human rights framework, I propose the health democracy which will is urgent 
necessary in the globalization. 
 
 
5.1 The Barriers between Access to Health and Intellectual Property 
It is no doubt that there are multiple barriers to access to health existing in the era 
of globalization.  
The lack of universal trust has seriously hindered establishment of a balanced 
system between access to health and intellectual property rights. Although the private 
property holder has certain legal rights to invention defined within the patent, the 
invention itself is a public good which should be benefit to universal. In other words, 
there are two simultaneous interests in an invention, one is the legal interest, and the 
other is the equitable interest in the invention as a public good.  
The first pillar is lack of human rights equity. 
Regarding to access to health, the people have no right to education. To be 
specifically, the citizen is lack of health care knowledge and relevant information. 
People who live in the developing area have no awareness of health protection at all. 
The cultural, social and geographical obstacles prevent health education, examination 
and treatment. They even have no idea about the intellectual property protection of 
their own traditional medicine knowledge and the utility of it. There are little well 
educated doctors in the poor area where need the more professional doctors and health 
aids. On the contrary, similar sentiment was seen in understanding the needs of 
patients. Physicians and the market both believe economic and access to health 
necessitate no understanding of patient needs, which deny the way for the patient to 
realize their universal right and ask for it and increase the patient illiteracy. 
Besides, the people have no right to health. Honestly, this problem is rooted in 
poverty, which results in an inability to pay for even the cheapest medicines, 
including generics. Other factors that impede access are taxes and tariffs that raise 
prices unnecessarily, and cultural factors such as discrimination. Some inappropriate 
intellectual property rights also enlarge this unbalance. Moreover, a chronic 
under-investment in healthcare infrastructure which has led to a lack of clinics and 
hospitals, poor distribution networks, low numbers of trained healthcare providers, 
and is a key factor as well.  
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Additionally, the people have no right to development. According to the World 
Bank, a per capita spend on healthcare of at least US$14 per year is required to 
provide a basic healthcare infrastructure.112 And the expenditure on health of many 
sub-Saharan African countries is even well below this. This economic and distribute 
unbalance result the non-restructure health development system. From a long-term 
perspective, it will form a huge barrier for global sustainable development. Significant 
additional external funding is essential for medicines and development of the 
infrastructure needed to deliver them. The International healthcare systems must be 
strengthened according to the requirement of fundamental human rights. As the 
current WHO Director General Margaret Chan said in her acceptance speech that: 
“Health systems are the tap root for better health. All the donated drugs in the world 
won’t do any good without an infrastructure for their delivery.”113 
Hence, it is a common knowledge that markets alone cannot be relied upon to 
achieve the society trust and interest balance. So we need to promote the human 
values at stake in intellectual property systems. This is clear, for example, from recent 
experiences in the areas of public health and education, where intellectual property 
has complicated progress toward meeting these basic public needs and foundation 
human rights.114 
The second pillar is the urgent need of economic equity.  
The high price of drugs or huge cost of health service in developing country and 
the gap between urban and rural area give raise the unequal distribution of health care 
resources. For instance, there are limited availability and accessibility of medical 
professionals in some remote rural areas and least developing countries are lack of 
laboratory equipment, health centers and hospital infrastructure. Poverty which results 
in an inability to pay for even the cheapest medicines is an obstacle to improving 
healthcare in the developing world. But at the same time, the high cost of invention, 
research and patent has increased the price of the Access to health. The right holder in 
order to finance further research has added the cost into the payment of patients. The 
balance of Access to health and Intellectual Property seems as the cost vs. the profit. 
Prices matter, because medicines account for up to 80% of health expenditure in some 
developing countries and thus strongly influence overall access to health care. In 
many developing countries there are no general health insurance systems. Most 
people must finance their medicines privately and at the time of the illness. WHO 
estimates that 50–90 % of such “out-of-pocket” spending for health care is spent on 
patent monopolizes medicines. The lack of insurance of course makes high medicine 
prices extra burdensome for poor people.115 
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However, I think it is the government or any other national and international duty 
holders who should take the obligation to support, not the people who indeed lack of 
health but cannot afford it. As stated in the Doha declaration: “We recognize that IP 
protection is important for the development of new medicines. We also recognize the 
concerns about its effects on prices”. At the same time, we should take the human 
rights into consideration and change the current intellectual property regime to make 
the access to health as an element of it as well, which will be a practical way to 
decline the unbalance of the price related problem. 
The third pillar is no legal equity. 
Nowadays, over 95% of the 325 drugs on the WHO Essential Medicine List are 
not patent protected and yet the WHO says that 30% of people in developing 
countries do not have reliable access to these drugs. This rises to 2/3rds of populations 
in Africa and parts of Asia.116 First line treatments for killer diseases like malaria and 
TB are available as generic products at very low cost, and yet many people are denied 
access to them because there have little legal certification of these health products. 
From this perspective, we need to seek a new system to adapt the intellectual property 
products market and fulfill human rights obligation immediately. 
On the one hand, because most intellectual property rights, especially patents, are 
time-limited rights and the public interest requires that creative and innovative works 
ultimately become free for all to use as part international intellectual property policy 
affects a broad range of interests within society, not just those of rights holders. Thus, 
intellectual property rights should be conducted through mechanisms of transparency 
and openness that encourage broad public participation. New rules of this human 
rights based intellectual framework should be made within the existing forums 
responsible for other related policy, where both developed and developing countries 
have full representation, and where the texts of and forums for considering proposals 
are open. All new international intellectual property standards must be subject to 
democratic balances, including domestic legislative approval and opportunities for 
judicial review.117 Although the right to democracy is only guaranteed in ICCPR, 
some human rights professor raised the opinion of health democracy. The link 
between ICESCR and ICCPR and the human rights is universal to be protected has 
been a strong support to it. In my opinion, it is no doubt that the health democracy can 
be an efficient way for people to fulfill their access to health in many situations 
despite fighting with intellectual property protection. Moreover, democracy should be 
an all in one term and adapted to the need of the global society.  
On the other hand, to focus on patents as the only barrier to access is misleading 
and counter-productive. Patent protection stimulates and fundamentally underpins the 
continued research and development for new and better medicines for diseases 
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including those which occur in the developing world. So, the public domain serves as 
a foundation of cultural heritage and scientific knowledge from which future creators 
and inventors necessarily to be underlined. A group of related civil society movements 
has emerged to promote the benefits of the public domain or openness, including 
through open licensing, open access, open educational resources, open data, open 
standards, open government, and related open information policies.118It leaves a huge 
task to finish and balance for the authority and law makers.  
Consequently, it cannot be denied that intellectual property particularly patent, to 
some extent, generally affect the access condition, such as medicine prices, which 
result many other trust problems like absence of clinics, doctors, information or equity 
and safe distribution. High medicine prices are certainly not the only thing obstacle to 
global health, which also emphasized clearly by both WHO and UNAIDS, but still the 
main cause in this global situation. As the globalization caused by migration and the 
multinational trade, this intellectual property monopoly and competition influence has 
been enlarged and become to the barriers of human being to enjoy their human dignity 
and access to health. However, because human rights are universal to everyone, it 
should be a surefire way for authority to balance and control the intellectual property 
and the access blank. In particularly, human rights are fundamental and available 
globally, so it requires the universal access, which is the same as the aim of 
international affairs. Hence taking into account of human rights spirit must be the 
most efficient way for eliminating the barriers I mentioned before.  
 
5.2 Innovation and Intellectual Property 
In the context of public health, it is vital to ensure that the individuals should 
maintain the health, the life and innovation. These three organs should be balanced by 
intellectual property and none of them could be infringed and its hypertrophy will 
obstruct the role of others. So we should find the equilibrium of access to health and 
health related innovation. 
Several motivations are impressed by the innovation. First, innovation is 
important for both, driving economic progress and competitiveness despite of the 
economic level of the development. It has a global effect. And many governments are 
putting innovation at the center of their growth strategies. Second, there is increasing 
awareness that the definition of innovation has broadened, which is no longer 
restricted to R&D laboratories and published scientific papers. Innovation has formed 
many models such as social innovation and business model innovation and is more 
general and horizontal in nature. Finally, recognizing and celebrating innovation in 
emerging markets is seen as critical for inspiring people, especially the next 
generation of entrepreneurs and innovators.119 
What’s more, it seems that the intellectual property regime is a unique man-made 
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law system to regulate the market. On the one hand, it can reward an exclusive rights 
for some righholders to protect their rights, on the other hand, it will be a tool or 
formulate for the market competition, which is established during the economy 
development. The big company can use it as a protection and instrument for the 
competition, like Apple. It promotes the innovation and gain on the market profit for 
rightholders. Only the company who can manage this system and control the society 
human rights obligation can survive and develop. The patent and other intellectual 
property rights are the market lever for the rightholder and the whole society. For 
example, some generic products and research cannot be grant patent in some countries 
due to the ethic reasons, which is a way the intellectual property tend to protection the 
human dignity. But this exclusive cannot be treated as the barriers for innovation, on 
the contrary, it does not prevent the innovative public research. And all the people can 
have the right to benefit it. 
As a possible alternative, I propose a competitive financing scheme that would 
work through R&D investment intermediates. These R&D funds would be licensed 
and regulated (like pension funds). Their role would be to manage R&D assets on 
behalf of consumers. Individuals (or employers) would be required to make minimum 
contributions into R&D funds, much as there are mandatory contributions to social 
security or health insurance or to pension funds. 120Government would set the 
required contribution, but the individual (or employer) would be free to choose the 
particular intermediate that received their contributions. Intermediates would compete 
to attract funds to invest in R&D on the basis of their prowess for drug development 
and upon their priorities.121 Different business models for financing R&D could be 
tested in such a market, with intermediates experimenting with prize systems, direct 
investments in profit or nonprofit entities, open collaborative public good models, or 
other approaches.  
 
5.3 Human Rights Make Access to Health Global and Universal 
We have to admit that although most countries have incorporated access to 
health as an element to human rights in their Constitution, however in practice, not all 
individuals had been equally able to exercise it. It still has a long way to go. 
Human rights must be fundamental, universal in the sense that it is globally and 
very widely recognized and guaranteed to everyone. The concern is legitimate and 
must be taken seriously, at the same time, the list of human rights can never be 
considered as closed. Although it is impossible to figure out the human dignity in the 
future, the foundation of all human rights should be guaranteed according to the social 
reality. The capable of human rights should formulate sufficiently precise as to give 
rise to legal obligations of state and the international cooperation. Turn to the 
intellectual property regime, the universal access also meets with the requirement of 
the global intellectual property market. So, these two systems have a same basement 
and interaction.  
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To extent, we need to ensure health democracy based on the access to universal 
human rights. 
First, the legal recognition of right to health as a social right was already there 
when the debate around the reform started, but its actual implementation was only 
benefiting certain sectors of the population not all. What is lacking is the definition of 
the explicit entitlements that ensued from the claim, and the global financial 
instruments. The effective health services for all according to universal human rights 
should be translated and present in these instrument, individual and public financial 
decisions. 
Furthermore, according to Brachet, to transform health care into a real social 
right requires, there are two important things: a defined set of health benefits all 
citizens, regardless of their labor or socio-economic status. Everyone should receive 
and can legally demand or established mechanisms through which the costs of these 
benefits will be distributed to guarantee their financial viability.122 Thus, because of 
the universal human rights, in the global marketing shifting, all the Intellectual 
property holders and rights holders should realize their obligation to respect the 
universal human rights and balance the individual rights to universal accessible.  
For illustration, a new technology is developing in healthcare called 
“personalized medicine”, in which prescription medications are chosen based on each 
person’s genetic profile. Three out of four patients have not heard of personalized 
medicine. Given the perceptions of biopharma and managed care that personalized 
medicine will increase the safety and effectiveness of medications, this presents an 
opportunity to educate patients on the concept. How can patients impact drug 
development? There is a definite trend towards patients increasingly taking active 
control of their health, sharing information about treatments with each other and 
seeing the healthcare system as a partner in making decisions and access their right to 
health personalize.123This new health care form is secured by universal human rights 
in the globalization. People no matter the territory and other factors can enjoy an 
equity access the health and make it personally.  
Second, the effective exercise of human rights is a key component of citizenship 
and should be considered an intrinsic objective of all democracies. Universal and 
global access to health reduces poverty, improves educational outcomes, enhances 
productivity, and prompts economic growth. Apparently, prosperity and a fair 
distribution of its benefits contribute to democratic stability.124 So, owing to the 
universal human rights theories and its basic equity accessibility, the recognition of 
health as a universal value favors the establishment of political agreements. These 
agreements, in turn, help to build social cohesion which nourishes democratic 
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globalization societies. 
Finally, the implementation of human rights in access to health under the 
intellectual property implies the use of democratic procedures, which also favors the 
consolidation of not health democracy but also other democracy ensured in the 
international human rights law. Salient among them are public deliberation, definition 
of entitlements, transparency, and accountability. Hence, the approval of the legal 
reforms required broad public discussion involving all the main global health related 
actors: Health authorities, political parties, academic institutions, and NGOs. Clearly 
defined benefits have ensured that those who avail themselves of the public insurance 
scheme know the services and treatments to which they are entitled. At the same time, 
the implementation of the reform has fostered other important procedures including 
access to public information, open evaluation and dissemination of report cards, all of 
which are contributing to the consolidation of a democratic culture.125 
Therefore, the reforms of extending the access to health to all the population 
have strengthened the procedures and institutions of democracy. Certainly, the 
democratization of health can contribute to the health of democracy among the world. 
Human rights based framework can ensure all the social movement like globalization 
in the line of universal human rights fulfillment and guarantee the universal 
democracy in the process of globalization. It is only way to secure and balance human 
dignity with the global economic benefit especially in the intellectual property era. 
 
 
To be concluded, in the globalization, equally access, recognition of access to 
health as a universal value favors the establishment of international legal agreements. 
These agreements, in turn, help to build social cohesion which nourishes democratic 
societies.126 We should use the human rights values to regular other decision making 
and eliminate the global barriers. Simultaneously, the intellectual property as I 
analyzed in this part, will not be a block for the innovation and accessibility, contrarily, 
it will be an insensitive and promotion for development. We need acknowledge and 
utilize it in the globalization. This is not only a trend but also a demand of the global 
society and universal human rights requirement. 
 
 
 
 
                                                             
125 Julio Frenk and Octavio Gómez-Dantés. “The Democratization of Health in Mexico: Extending” .Swiss human 
rights book, 2009. 
126 Julio Frenk and Octavio Gómez-Dantés.”The Democratization of Health in Mexico: Extending the Right to 
Health Care”. Swiss human rights book, 2009. 
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6. Conclusion 
 
The call for balance of Access to Health and Intellectual Property during the 
globalization has raised profound legal question and practice challenges alike for a 
long time. In the global society nowadays, the calling is gaining growing spirit. 
Although most people are in favor of balance, there are many blocks on the way to 
fulfill the accessible set by the characteristic of Intellectual Property and unequal 
economy world affairs. 
This paper has provided a review of Access to Health issues in the era of 
globalization under the Intellectual Property system and analysis the existing legal 
framework seeking to find out the significant link between the two regimes in the 
unique globalization background.  
First of all, the issue will only be settled when we addressed three big barriers 
efficiently, which is namely the lack of trust. Hence, the most important thing for us, 
human right person, is to raise the personal awareness of health care of local people 
and make the health knowledge accessible, affordable and borderless. We aim to build 
the trust between Human Rights and Intellectual Property.  
Moreover, because access to health is a complex and multi-faceted problem in 
the era of globalization, the challenges can only be properly addressed through 
partnership between developed and developing country governments, international 
organizations, the industry and charitable organizations. The cooperation among the 
world is inevitably necessary to achieve the balance. Besides the relevant agenda the 
international organizations have adopted, like global drug strategy, implement of 
compulsory license in the world trade market, I propose to find new measures to 
promote the relationship. We should attempt to create an effective legal cooperation 
system for the unbalance and universal access problems in the globalization. Only the 
global and universal methods can balance unequal of the price and accessible to 
health.  
What is more, we need to respect the cohesion of international human rights, 
intellectual property and the economic development in the globalization. On one hand 
we have to protect the Intellectual Property Right of the right holder; on the other 
hand we should respect and fulfill the universal Human Right involved in this field. 
Obviously, it is an interactive relationship. We should insist on figuring out the 
original problem like the economic theories of high price and the weakness in the 
intellectual property nowadays. For example, if we want to cut down the cost of 
essential medicines, the key point is to reduce the extra service and patent fee paid for 
the inter-management like WIPO. We should create a win-win situation for both the 
Human Right and Intellectual Property Right. 
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Finally, the implementation of the access to health implies the use of democratic 
procedures, which also favors the consolidation of democracy. The universal exercise 
of social rights can also contribute to the consolidation of democracy. 127Universal 
access to health care reduces poverty, improves educational outcomes, enhances 
productivity, and prompts economic growth. Prosperity and a fair distribution of its 
benefits contribute to democratic stability.128  
Therefore, although the globalization has result a bind of legal, economic and 
social problems recently, we can apply the human rights which are fundamental and 
universal existed to balance the varied interests. We should add the health democracy 
into the human rights regime and use it as a protection for the intellectual property 
threat. Besides, we need to adjust the intellectual property law and make it as a global 
standard under the framework of human rights. It should turn to a legal arm for the 
people and secure their right to access to the health in the global range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
127 Julio Frenk and Octavio Gómez-Dantés. “The Democratization of Health in Mexico: Extending the Right to 
Health Care”. Swiss human rights book, 2009. 
128 T, Karl. “cuánta democracia acepta la desigualdad?”69 Este País, 1996. Page 46–51. 
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